SCHEMBL423834

SCHEMBL423834

CCOC(=O)c1cc(Br)c(-c2cc(F)cc(C#N)c2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.43
PGR P06401 1/20 0.40
PTPN2 P17706 2/20 0.39
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 2/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
EPAS1 Q99814 3/20 0.37
ARNT P27540 2/20 0.37
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
POLQ O75417 1/20 0.36
GRM5 P41594 1/20 0.35
GRM6 O15303 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421731 0.82 MAPK14 (0.46) MAPK14PTPN2KDM4EALDH1A1HPGD
SCHEMBL2505209 0.82 PGR (0.41) PGREPAS1ARNTFNTAFNTB
SCHEMBL3602085 0.79 MAPK14 (0.65) MAPK14PTPN2KDM4EALDH1A1HPGD
SCHEMBL420399 0.79 MAPK14 (0.51) MAPK14PGRPTPN2KDM4EALDH1A1
SCHEMBL12942238 0.76 PTGS2 (0.42) PGRKDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL422503 0.74 MAPK14 (0.48) MAPK14KDM4EALDH1A1HPGDNPC1
SCHEMBL23384739 0.72 CA12 (0.49)
SCHEMBL31237155 0.72 CA12 (0.49)
SCHEMBL3609166 0.71 MAPK14 (0.61) MAPK14KDM4EALDH1A1HPGDNPC1
SCHEMBL27005478 0.71 PRKCZ (0.53) MAPK14PTPN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 MAPK14 2294/4885PGR 2778/4885PTPN2 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.